CERA

Hope in sight TM

Our research is bringing hope to people affected by vision loss and blindness

Donate Now

Hope in sight for inherited retinal disease

A new study is identifying patients with inherited retinal diseases who may suitable for future trials.

Advances in gene and cell therapies mean that treatments to stop vision loss could soon be on the horizon in Australia.

Video

In this video, learn about CERA’s research into gene therapies that could halt or even reverse vision loss in patients with conditions such as inherited retinal diseases and glaucoma.

Research

A world-leading multidisciplinary research project, investigating age-related macular degeneration and the factors that make some people more likely to lose their vision.

Free guide

This free guide gives you an essential introduction to age-related macular degeneration (AMD), and a snapshot of the latest world-leading research at CERA.

Donate to CERA

With your support, there’s hope in sight.

Your gift will contribute to our world-leading vision research, making a real difference to people affected by vision loss and blindness.

Donate now

Take part in research

We conduct world-leading clinical trials for a range of eye conditions.

Learn more about taking part in clinical trials for conditions like age-related macular degeneration, glaucoma, diabetic retinopathy and more.

Learn more

Latest News


Research

27 October 2020

CERA’s research into the effectiveness of vitamin B3 in preventing nerve cell damage in glaucoma has received a major funding boost from Glaucoma Australia.

News

27 October 2020

The Centre for Eye Research Australia has been named on the AFR BOSS Most Innovative Companies list for 2020.

News

27 October 2020

From a young age, CERA Senior Research Fellow Dr Zhichao Wu wanted to improve public health.

News

27 October 2020

CERA Research Fellow Dr Carla Abbot has earned a place in the veski inspiring women in STEM side by side program for emerging leaders.

Eye-news emails are sent to subscribers once a month

Newsletter Subscribe
Receive Appeals